Pfizer has cleared the way to launching its Zirabev bevacizumab biosimilar in the US at the end of this year by settling global patent litigation with Roche and its Genentech affiliate. Amgen’s Mvasi (bevacizumab-awwb) is currently the only biosimilar to Avastin on the market.
Pfizer Prepares For Year-End US Bevacizumab Launch
Pfizer has cleared the way to launching its Zirabev bevacizumab biosimilar in the US on 31 December this year following a patent-litigation settlement with Roche.
